TY - JOUR
T1 - Hypophosphatemia in acute liver failure of a broad range of etiologies is associated with phosphaturia without kidney damage or phosphatonin elevation
AU - Acute Liver Failure Study Group
AU - Zechner, CHRISTOPH
AU - ADAMS-HUET, BEVERLEY
AU - GREGORY, BLAKE
AU - NEYRA, JAVIER A.
AU - RULE, JODY A.
AU - LI, XILONG
AU - RAKELA, JORGE
AU - MOE, ORSON W.
AU - LEE, WILLIAM M.
N1 - Funding Information:
Conflict of Interest: All authors have read the journal's authorship agreement and policy on disclosure of potential conflicts of interest. Dr. Lee receives research support from Merck, Conatus, Intercept, Bristol-Myers Squibb, Novo Nordisk, Synlogic, Eiger, Cumberland, Exalenz, Instrumentation Laboratory and Ocera Therapeutics, now Mallinckrodt Pharmaceuticals. He has consulted for Genentech, Forma Therapeutics, Affibody, Ambys and Seattle Genetics. Dr. Moe performed paid consultations for Allena Pharmaceutical, Alnylam, Ardelyx, Applied Therapeutics, Dicerna, and Tricida. The remaining authors declare no conflict of interest. Salary support for C. Z. was provided by NIH grants T32DK007307 and K08DK106569. Project support was provided by the UT Southwestern George M. O'Brien Kidney Research Center (NIH P30DK079328), the National Institutes of Health (R01DK081423, R01DK115703, and R01DK091392) and the Seldin-Pak Funds for Clinical-Metabolic Research. The Acute Liver Failure Study Group has been supported since 1997 by National Institute of Diabetes, Digestive and Kidney Diseases, Grant U01DK058369 and by additional funds by the George A. Roberts Fund in the Southwestern Medical Foundation. None of these funding sources influenced design and execution of this study. Author contributions are as follows: C. Z. B. G. J. A. N. J. R. O. W. M. and W. M. L. designed the study. C. Z. B. A. H. X. L. and J. A. R. analyzed data. C. Z. O. W. M. and W. M. L. wrote the manuscript with input from all authors. The authors greatly appreciate technical assistance of Johanne Pastor, Katherine Bosler, and Preston Burnley. The authors wish to thank Naim Maalouf for critical review of the manuscript. The Acute Liver Failure Study Group Registry is registered under ClinicalTrials.gov identifer NCT00518440 (URL: https://www.clinicaltrials.gov/ct2/show/NCT00518440).
Funding Information:
Salary support for C. Z. was provided by NIH grants T32DK007307 and K08DK106569 . Project support was provided by the UT Southwestern George M. O'Brien Kidney Research Center ( NIH P30DK079328 ), the National Institutes of Health ( R01DK081423 , R01DK115703 , and R01DK091392 ) and the Seldin-Pak Funds for Clinical-Metabolic Research . The Acute Liver Failure Study Group has been supported since 1997 by National Institute of Diabetes, Digestive and Kidney Diseases , Grant U01DK058369 and by additional funds by the George A. Roberts Fund in the Southwestern Medical Foundation . None of these funding sources influenced design and execution of this study.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/12
Y1 - 2021/12
N2 - Hypophosphatemia is a common and dangerous complication of acute liver failure (ALF) of various etiologies. While various mechanisms for ALF-associated hypophosphatemia have been proposed including high phosphate uptake into regenerating hepatocytes, acetaminophen (APAP)-associated hypophosphatemia was linked to renal phosphate wasting, and APAP-induced renal tubular injury was proposed as underlying mechanism. We studied 30 normophosphatemic and 46 hypophosphatemic (serum phosphate < 2.5 mg/dL) patients from the Acute Liver Failure Study Group registry with APAP- or non-APAP-induced ALF. Since kidney injury affects phosphate excretion, patients with elevated serum creatinine (>1.2 mg/dL) were excluded. Maximal amount of renal tubular phosphate reabsorption per filtered volume (TmP/GFR) was calculated from simultaneous serum and urine phosphate and creatinine levels to assess renal phosphate handling. Instead of enhanced renal phosphate reabsorption as would be expected during hypophosphatemia of non-renal causes, serum phosphate was positively correlated with TmP/GFR in both APAP- and non-APAP-induced ALF patients (R2 = 0.66 and 0.46, respectively; both P < 0.0001), indicating renal phosphate wasting. Surprisingly, there was no evidence of kidney damage based on urinary markers including neutrophil gelatinase-associated lipocalin and cystatin C even in the APAP group. Additionally, there was no evidence that the known serum phosphatonins parathyroid hormone, fibroblast growth factor 23, and α-Klotho contribute to the observed hypophosphatemia. We conclude that the observed hypophosphatemia with renal phosphate wasting in both APAP- and non-APAP-mediated ALF is likely the result of renal tubular phosphate leak from yet-to-be identified factor(s) with no evidence for proximal tubular damage or contribution of known phosphatonins.
AB - Hypophosphatemia is a common and dangerous complication of acute liver failure (ALF) of various etiologies. While various mechanisms for ALF-associated hypophosphatemia have been proposed including high phosphate uptake into regenerating hepatocytes, acetaminophen (APAP)-associated hypophosphatemia was linked to renal phosphate wasting, and APAP-induced renal tubular injury was proposed as underlying mechanism. We studied 30 normophosphatemic and 46 hypophosphatemic (serum phosphate < 2.5 mg/dL) patients from the Acute Liver Failure Study Group registry with APAP- or non-APAP-induced ALF. Since kidney injury affects phosphate excretion, patients with elevated serum creatinine (>1.2 mg/dL) were excluded. Maximal amount of renal tubular phosphate reabsorption per filtered volume (TmP/GFR) was calculated from simultaneous serum and urine phosphate and creatinine levels to assess renal phosphate handling. Instead of enhanced renal phosphate reabsorption as would be expected during hypophosphatemia of non-renal causes, serum phosphate was positively correlated with TmP/GFR in both APAP- and non-APAP-induced ALF patients (R2 = 0.66 and 0.46, respectively; both P < 0.0001), indicating renal phosphate wasting. Surprisingly, there was no evidence of kidney damage based on urinary markers including neutrophil gelatinase-associated lipocalin and cystatin C even in the APAP group. Additionally, there was no evidence that the known serum phosphatonins parathyroid hormone, fibroblast growth factor 23, and α-Klotho contribute to the observed hypophosphatemia. We conclude that the observed hypophosphatemia with renal phosphate wasting in both APAP- and non-APAP-mediated ALF is likely the result of renal tubular phosphate leak from yet-to-be identified factor(s) with no evidence for proximal tubular damage or contribution of known phosphatonins.
UR - http://www.scopus.com/inward/record.url?scp=85112493050&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112493050&partnerID=8YFLogxK
U2 - 10.1016/j.trsl.2021.07.003
DO - 10.1016/j.trsl.2021.07.003
M3 - Article
C2 - 34298149
AN - SCOPUS:85112493050
SN - 1931-5244
VL - 238
SP - 1
EP - 11
JO - Translational Research
JF - Translational Research
ER -